{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:55:32Z","timestamp":1791179732772,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/eurheartj\/ehag778","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:14:01Z","timestamp":1789672441000},"source":"Crossref","is-referenced-by-count":0,"title":["Weekly Journal Scan: Expanding the therapeutic options for adolescents with obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-3066","authenticated-orcid":false,"given":"Daniela","family":"Pedicino","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Largo A. Gemelli 8, Rome 00168 ,","place":["Italy"]},{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University, School of Medicine , Largo F. Vito 1, Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-0907","authenticated-orcid":false,"given":"Giovanna","family":"Liuzzo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Largo A. Gemelli 8, Rome 00168 ,","place":["Italy"]},{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University, School of Medicine , Largo F. Vito 1, Rome 00168 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100501385631000_ehag778-B1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa2601103","article-title":"Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy","volume":"395","author":"Rossano","year":"2026","journal-title":"N Engl J Med"},{"key":"2026100501385631000_ehag778-B2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMra2413445","article-title":"Hypertrophic cardiomyopathy","volume":"393","author":"Braunwald","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100501385631000_ehag778-B3","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1093\/eurheartj\/ehaf026","article-title":"Hypertrophic cardiomyopathy: prevalence of disease-specific red flags","volume":"46","author":"Maurizi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026100501385631000_ehag778-B4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/oxfordjournals.aje.a009291","article-title":"Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland","volume":"146","author":"Arola","year":"1997","journal-title":"Am J Epidemiol"},{"key":"2026100501385631000_ehag778-B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"2026100501385631000_ehag778-B6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biom15081098","article-title":"Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy: clinical trials and future challenges","volume":"15","author":"Kukowka","year":"2025","journal-title":"Biomolecules"},{"key":"2026100501385631000_ehag778-B7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026100501385631000_ehag778-B8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026100501385631000_ehag778-B9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026100501385631000_ehag778-B10","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026100501385631000_ehag778-B11","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100501385631000_ehag778-B12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jcmg.2025.07.019","article-title":"Long-term favorable cardiac remodeling in obstructive hypertrophic cardiomyopathy patients treated with mavacamten for up to 128 weeks: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100501385631000_ehag778-B13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag778\/71585882\/ehag778.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag778\/71585882\/ehag778.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:39:02Z","timestamp":1791178742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag778\/8861368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":13,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag778","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"ehag778"}}